MA53544A - Procédé de préparation de compositions de vaccin - Google Patents

Procédé de préparation de compositions de vaccin

Info

Publication number
MA53544A
MA53544A MA053544A MA53544A MA53544A MA 53544 A MA53544 A MA 53544A MA 053544 A MA053544 A MA 053544A MA 53544 A MA53544 A MA 53544A MA 53544 A MA53544 A MA 53544A
Authority
MA
Morocco
Prior art keywords
vaccine compositions
preparing vaccine
preparing
compositions
vaccine
Prior art date
Application number
MA053544A
Other languages
English (en)
Inventor
Zsolt Csiszovszki
Julianna Liszewicz
Orsolya Lorincz
Mónika Megyesi
Levente Molnár
Péter Páles
Katalin Pántya
Eszter Somogyi
Eniko Toke
József Toth
Original Assignee
Treos Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treos Bio Ltd filed Critical Treos Bio Ltd
Publication of MA53544A publication Critical patent/MA53544A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053544A 2018-09-04 2019-09-03 Procédé de préparation de compositions de vaccin MA53544A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1814362.8A GB201814362D0 (en) 2018-09-04 2018-09-04 Composition and process for preparing vaccine

Publications (1)

Publication Number Publication Date
MA53544A true MA53544A (fr) 2021-07-14

Family

ID=63920945

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053544A MA53544A (fr) 2018-09-04 2019-09-03 Procédé de préparation de compositions de vaccin

Country Status (17)

Country Link
US (3) US20200069786A1 (fr)
EP (1) EP3847185A1 (fr)
JP (1) JP2021535749A (fr)
KR (1) KR20210086610A (fr)
CN (1) CN113383009A (fr)
AU (1) AU2019334261A1 (fr)
BR (1) BR112021004075A2 (fr)
CA (1) CA3110923A1 (fr)
CL (1) CL2021000534A1 (fr)
CO (1) CO2021004028A2 (fr)
EA (1) EA202190669A1 (fr)
GB (1) GB201814362D0 (fr)
IL (1) IL281220A (fr)
MA (1) MA53544A (fr)
MX (1) MX2021002543A (fr)
SG (1) SG11202101881UA (fr)
WO (1) WO2020048995A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110651189A (zh) 2017-03-03 2020-01-03 特雷斯生物公司 肽疫苗
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
MX2021002449A (es) 2018-09-04 2021-08-05 Treos Bio Ltd Vacunas peptidicas.
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
US20230190902A1 (en) * 2020-05-29 2023-06-22 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法
EP3945320A1 (fr) * 2020-07-29 2022-02-02 Corporació Sanitària Parc Taulí Épitope amélioré pour la détection et/ou la quantification des auto-anticorps contre l'alpha-fétoprotéine
CA3196679A1 (fr) * 2020-10-28 2022-05-05 Jan Alenfall Peptides destines a etre utilises dans la pigmentation de la peau et des cheveux
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
CN114195861A (zh) * 2022-01-05 2022-03-18 许昌学院 亲和肽
CN115785204B (zh) * 2022-06-10 2024-02-13 河北博海生物工程开发有限公司 肺癌特异性分子靶标08及其用途
CN115785211A (zh) * 2022-06-10 2023-03-14 河北博海生物工程开发有限公司 肺癌特异性分子靶标04及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
WO2012051282A2 (fr) * 2010-10-14 2012-04-19 The Ohio State University Research Foundation Diagnostic et thérapie du cancer ciblés sur des protéines de type piwil2 (pl2l)
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
EP3369431A1 (fr) 2017-03-03 2018-09-05 Treos Bio Kft Vaccin
EP3370065A1 (fr) 2017-03-03 2018-09-05 Treos Bio Kft Peptides immunogènes
CN110651189A (zh) 2017-03-03 2020-01-03 特雷斯生物公司 肽疫苗

Also Published As

Publication number Publication date
JP2021535749A (ja) 2021-12-23
CN113383009A (zh) 2021-09-10
SG11202101881UA (en) 2021-03-30
US20220160854A1 (en) 2022-05-26
EA202190669A1 (ru) 2021-06-03
CA3110923A1 (fr) 2020-03-12
CO2021004028A2 (es) 2021-06-21
CL2021000534A1 (es) 2021-09-24
US20210236611A1 (en) 2021-08-05
AU2019334261A1 (en) 2021-03-18
BR112021004075A2 (pt) 2021-05-25
KR20210086610A (ko) 2021-07-08
WO2020048995A1 (fr) 2020-03-12
GB201814362D0 (en) 2018-10-17
IL281220A (en) 2021-04-29
US20200069786A1 (en) 2020-03-05
EP3847185A1 (fr) 2021-07-14
MX2021002543A (es) 2021-08-11

Similar Documents

Publication Publication Date Title
MA53544A (fr) Procédé de préparation de compositions de vaccin
MA54253A (fr) Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines
DK3068392T3 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
MA44238A (fr) Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r
GB2572275B (en) Method for preparing Foot-and-Mouth disease vaccine
MA52906A (fr) Procédé de préparation d'amg 416
MA54396A (fr) Procédé de préparation de n-phénylpyrazole-1-carboxamides
MA49472A (fr) Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole
MA42423A (fr) Procédé de préparation d'un revêtement
MA47022A (fr) Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
MA50517A (fr) Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole
CY1122172T1 (el) Τροποποιητες θειαζολης των a3 υποδοχεων αδενοσινης
EP3365332A4 (fr) Procédé de préparation d'intermédiaire pour dérivé d'oxazolidinone
DK3737678T3 (da) Fremgangsmåde til fremstilling af disubstituerede diaryloxybenzoheterodiazolforbindelser
DK3020358T3 (da) Fremgangsmåde til fremstilling af tandprotese
MA42264A (fr) Procédé de préparation d'oltipraz
MA53346A (fr) Composition de vaccin muqueux pour la mastite bovine
EP3766890C0 (fr) Procédé de préparation d'un composé de polysilane cyclique
SG11202001937TA (en) Method for producing influenza ha split vaccine
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
MA49555A (fr) Procédé amélioré de préparation d'imetelstat
ZA202103976B (en) Immunogenic compositions for treatment of hepatitis b
MA55757A (fr) Procédé de préparation de formulations peptidiques stables
MA50263A (fr) Composition a visée détoxifiante pour administration par voie orale et son procédé de préparation
MA50371A (fr) Procédé de préparation de dérivés spiro